Jella An is an Ophthalmology physician. OpenAlex indexes 45 publications with 684 citations (h-index 13); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
One Hospital Drive
Columbia, MO 652120001
Telephone
573-882-1506Provider last certified this registry record 27 Apr 2022.
Clinical trials
- Direct vs Standard SLT for Glaucoma: A Noninferiority Trial
Sponsor: Medical University of South Carolina
Overall officialRecruitingNCT07408154 - Direct vs. Conventional SLT in Open-Angle Glaucoma: A RCT
Sponsor: Medical University of South Carolina
Overall officialEnrolling, by, invitationNCT06925477
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
19 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alcon Vision LLCProgram year202549 payments$49,682openpaymentsdata.cms.gov ↗
- Sight Sciences, Inc.Program year202519 payments$15,415openpaymentsdata.cms.gov ↗
- Bausch & Lomb Americas Inc.Program year202512 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
87.9%Prostaglandin Analog47.3%Latanoprost81%Tafluprost8%Lumigan8%Travoprost2%Bimatoprost2%Part D<11 patientsCarbonic Anhydrase Inhibitor20.7%Dorzolamide-Timolol81%Simbrinza10%Dorzolamide Hcl9%Part D<11 patients+ 4 more classes in this area
Cardiovascular
6.2%Beta blocker6.2%Timolol Maleate100%Part D≥41 patientsMusculoskeletal
3.7%Cyclooxygenase Inhibitor3.7%Ketorolac Tromethamine100%Part D≥39 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Clinical Outcomes of Hydrus Microstent Implantation for Open-Angle Glaucoma
Ophthalmology Glaucoma
2025 - Outcomes of MicroPulse® Transscleral Laser Therapy Using the Revised MicroPulse P3® Delivery Device
JOURNAL OF CURRENT GLAUCOMA PRACTICE
2025 - 0590 Cell-specific genetic effects of topical glucocorticoids in human skin
Journal of Investigative Dermatology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Emily Chew, MD
National Eye Institute
Robert Weinreb, MD
University of California San Diego
Harry Quigley, MD
Johns Hopkins University School of Medicine
Joel Schuman, MD
Wills Eye Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”